211 related articles for article (PubMed ID: 22348348)
1. Orally active lysophosphatidic acid receptor antagonist attenuates pancreatic cancer invasion and metastasis in vivo.
Komachi M; Sato K; Tobo M; Mogi C; Yamada T; Ohta H; Tomura H; Kimura T; Im DS; Yanagida K; Ishii S; Takeyoshi I; Okajima F
Cancer Sci; 2012 Jun; 103(6):1099-104. PubMed ID: 22348348
[TBL] [Abstract][Full Text] [Related]
2. LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites.
Komachi M; Tomura H; Malchinkhuu E; Tobo M; Mogi C; Yamada T; Kimura T; Kuwabara A; Ohta H; Im DS; Kurose H; Takeyoshi I; Sato K; Okajima F
Carcinogenesis; 2009 Mar; 30(3):457-65. PubMed ID: 19129242
[TBL] [Abstract][Full Text] [Related]
3. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1.
Yamada T; Sato K; Komachi M; Malchinkhuu E; Tobo M; Kimura T; Kuwabara A; Yanagita Y; Ikeya T; Tanahashi Y; Ogawa T; Ohwada S; Morishita Y; Ohta H; Im DS; Tamoto K; Tomura H; Okajima F
J Biol Chem; 2004 Feb; 279(8):6595-605. PubMed ID: 14660630
[TBL] [Abstract][Full Text] [Related]
4. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases.
Boucharaba A; Serre CM; Guglielmi J; Bordet JC; Clézardin P; Peyruchaud O
Proc Natl Acad Sci U S A; 2006 Jun; 103(25):9643-8. PubMed ID: 16769891
[TBL] [Abstract][Full Text] [Related]
5. Lysophosphatidic acid (LPA)-induced vascular endothelial growth factor (VEGF) by mesothelial cells and quantification of host-derived VEGF in malignant ascites.
Sako A; Kitayama J; Shida D; Suzuki R; Sakai T; Ohta H; Nagawa H
J Surg Res; 2006 Jan; 130(1):94-101. PubMed ID: 16171822
[TBL] [Abstract][Full Text] [Related]
6. N-WASP Control of LPAR1 Trafficking Establishes Response to Self-Generated LPA Gradients to Promote Pancreatic Cancer Cell Metastasis.
Juin A; Spence HJ; Martin KJ; McGhee E; Neilson M; Cutiongco MFA; Gadegaard N; Mackay G; Fort L; Lilla S; Kalna G; Thomason P; Koh YWH; Norman JC; Insall RH; Machesky LM
Dev Cell; 2019 Nov; 51(4):431-445.e7. PubMed ID: 31668663
[TBL] [Abstract][Full Text] [Related]
7. LPA receptor1 antagonists as anticancer agents suppress human lung tumours.
Zhao PF; Wu S; Li Y; Bao G; Pei JY; Wang YW; Ma Q; Sun HJ; Damirin A
Eur J Pharmacol; 2020 Feb; 868():172886. PubMed ID: 31866407
[TBL] [Abstract][Full Text] [Related]
8. Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers.
David M; Sahay D; Mege F; Descotes F; Leblanc R; Ribeiro J; Clézardin P; Peyruchaud O
PLoS One; 2014; 9(5):e97771. PubMed ID: 24828490
[TBL] [Abstract][Full Text] [Related]
9. Lysophosphatidic acid stimulates activation of focal adhesion kinase and paxillin and promotes cell motility, via LPA1-3, in human pancreatic cancer.
Liao Y; Mu G; Zhang L; Zhou W; Zhang J; Yu H
Dig Dis Sci; 2013 Dec; 58(12):3524-33. PubMed ID: 24061591
[TBL] [Abstract][Full Text] [Related]
10. Lysophosphatidic acid signaling via LPA
Fukushima K; Takahashi K; Yamasaki E; Onishi Y; Fukushima N; Honoki K; Tsujiuchi T
Exp Cell Res; 2017 Mar; 352(1):139-145. PubMed ID: 28189636
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model.
Xu X; Prestwich GD
Cancer; 2010 Apr; 116(7):1739-50. PubMed ID: 20143443
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of invasion of hepatocellular carcinoma cells through lysophosphatidic acid receptor.
Lou L; Chen YX; Jin L; Li X; Tao X; Zhu J; Chen X; Wu S; Ye W; He J; Ding G
J Int Med Res; 2013 Feb; 41(1):55-63. PubMed ID: 23569130
[TBL] [Abstract][Full Text] [Related]
13. Involvement of oncogenic K-ras on cell migration stimulated by lysophosphatidic acid receptor-2 in pancreatic cancer cells.
Yoshikawa K; Tanabe E; Shibata A; Inoue S; Kitayoshi M; Okimoto S; Fukushima N; Tsujiuchi T
Exp Cell Res; 2013 Feb; 319(3):105-12. PubMed ID: 23041208
[TBL] [Abstract][Full Text] [Related]
14. Selective activator protein-1 inhibitor T-5224 prevents lymph node metastasis in an oral cancer model.
Kamide D; Yamashita T; Araki K; Tomifuji M; Tanaka Y; Tanaka S; Shiozawa S; Shiotani A
Cancer Sci; 2016 May; 107(5):666-73. PubMed ID: 26918517
[TBL] [Abstract][Full Text] [Related]
15. LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study.
Yu X; Zhang Y; Chen H
BMC Cancer; 2016 Nov; 16(1):846. PubMed ID: 27809800
[TBL] [Abstract][Full Text] [Related]
16. MIF inhibitor, ISO-1, attenuates human pancreatic cancer cell proliferation, migration and invasion in vitro, and suppresses xenograft tumour growth in vivo.
Cheng B; Wang Q; Song Y; Liu Y; Liu Y; Yang S; Li D; Zhang Y; Zhu C
Sci Rep; 2020 Apr; 10(1):6741. PubMed ID: 32317702
[TBL] [Abstract][Full Text] [Related]
17. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2).
So J; Wang FQ; Navari J; Schreher J; Fishman DA
Gynecol Oncol; 2005 Jun; 97(3):870-8. PubMed ID: 15919106
[TBL] [Abstract][Full Text] [Related]
18. LPA receptor 2 mediates LPA-induced endometrial cancer invasion.
Hope JM; Wang FQ; Whyte JS; Ariztia EV; Abdalla W; Long K; Fishman DA
Gynecol Oncol; 2009 Jan; 112(1):215-23. PubMed ID: 19019417
[TBL] [Abstract][Full Text] [Related]
19. Lysophosphatidic acid enhances human hepatocellular carcinoma cell migration, invasion and adhesion through P38 MAPK pathway.
Zhu B; Shi S; Ma YG; Fan F; Yao ZZ
Hepatogastroenterology; 2012 May; 59(115):785-9. PubMed ID: 22020916
[TBL] [Abstract][Full Text] [Related]
20. TM4SF1 Regulates Pancreatic Cancer Migration and Invasion In Vitro and In Vivo.
Cao J; Yang JC; Ramachandran V; Arumugam T; Deng DF; Li ZS; Xu LM; Logsdon CD
Cell Physiol Biochem; 2016; 39(2):740-50. PubMed ID: 27459514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
